FDA Inspection 1097116 — SAMYANG BIOPHARMACEUTICALS CORP.
The FDA completed an inspection of SAMYANG BIOPHARMACEUTICALS CORP. on June 3, 2019 in Seongnam. The inspection was classified NAI (No Action Indicated — no objectionable conditions were found). Product area: Devices.
Inspection Details
- Classification
- No Action Indicated (NAI) (NAI)
- End Date
- June 3, 2019
- Fiscal Year
- 2019
- Product Type
- Devices
- Project Area
- Compliance: Devices
- Location
- Seongnam (Korea (the Republic of))